Analysis of clinical significance of HDAC8 in colon cancer and its relationship with immune infiltration based on bioinformatics

doi:10.3877/cma.j.issn.1674-0793.2024.04.007

Abstract

Abstract:

Objective

To investigate the prognosis, expression of histone acetylation and its correlation with immune infiltration in colon cancer.

Methods

Univariate and multivariate Cox regression and Kaplan-Meier curve were utilized to evaluate the relationship between HDAC8 gene expression and prognosis of COAD patients. GO enrichment analysis was performed for the potential role of HDAC8 in colon cancer. The connection between HDAC8 and tumor infiltrating immune cells was analyzed based on ESTIMATE, CIBERSORT and ssGSEA.

Results

Cluster analysis results showed that three acetylation modification subgroups were identified. The highly expressed HDAC8 in Group3 was upregulated in colon cancer tissues and associated with poor prognosis. HDAC8 was closely associated with tumor immune microenvironment such as stromal, immune scores and tumor purity. HDAC8 expression indicated significantly negative correlations with the infiltration of cells such as dendritic cells, CD8⁺ T cells, B cells and NK cells. It was negatively correlated with the activation, maturation, cytotoxicity and costimulatory scores of dendritic cell and CD8⁺ T cells.

Conclusions

The expression of HDAC8 is closely related to the prognosis of colon cancer patients. It may affect the maturation of dendritic cells and T cells, participate in the formation of dysfunctional immune microenvironment in tumor tissues, and regulate the development of colon cancer.

Key words: Colonic neoplasms, Histone acetylation, HDAC8, Bioinformatics, Prognosis, Immune infiltration

Yiquan Li, Yubin Xie, Hong Hu, Yanru Zhang, Tufeng Chen. Analysis of clinical significance of HDAC8 in colon cancer and its relationship with immune infiltration based on bioinformatics[J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(04): 275-281.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2024.04.007

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2024/V18/I04/275

Figures/Tables 6

References 18

[1]	Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA Cancer J Clin, 2024, 74(1): 12-49.
[2]	Huang J, Lucero-Prisno DE 3rd, Zhang L, et al. Updated epidemiology of gastrointestinal cancers in East Asia[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(5): 271-287.
[3]	Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2023, 34(1): 10-32.
[4]	Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN[J]. Gut, 2023, 72(2): 338-344.
[5]	Wang P, Wang Z, Liu J. Role of HDACs in normal and malignant hematopoiesis[J]. Mol Cancer, 2020, 19(1): 5.
[6]	Palamaris K, Tzimou LM, Levidou G, et al. Histone deacetylases (HDACs): promising biomarkers and potential therapeutic targets in thymic epithelial tumors[J]. Int J Mol Sci, 2023, 24(5): 4263.
[7]	Huang C, Shu Y, Zhu Y, et al. Discovery of non-substrate, environmentally sensitive turn-on fluorescent probes for imaging HDAC8 in tumor cells and tissue slices[J]. Bioorg Med Chem, 2022, 68: 116821.
[8]	Kim JY, Cho H, Yoo J, et al. Pathological role of HDAC8: cancer and beyond[J]. Cells, 2022, 11(19): 3161.
[9]	Yang W, Feng Y, Zhou J, et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma[J]. Sci Transl Med, 2021, 13(588): eaaz6804.
[10]	Tang X, Li G, Su F, et al. HDAC8 cooperates with SMAD3/4 complex to suppress SIRT7 and promote cell survival and migration[J]. Nucleic Acids Res, 2020, 48(6): 2912-2923.
[11]	Blaszczak W, Liu G, Zhu H, et al. Immune modulation underpins the anti-cancer activity of HDAC inhibitors[J]. Mol Oncol, 2021, 15(12): 3280-3298.
[12]	Amin SA, Khatun S, Gayen S, et al. Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?[J]. Eur J Med Chem, 2023, 258: 115594.
[13]	Kim JY, Cho H, Yoo J, et al. HDAC8 deacetylates HIF-1α and enhances its protein stability to promote tumor growth and migration in melanoma[J]. Cancers (Basel), 2023, 15(4): 1123.
[14]	Wang F, Jin Y, Wang M, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: A randomized phase 2 trial[J]. Nat Med, 2024, 30(4): 1035-1043.
[15]	Zhao C, Chen D, Suo F, et al. Discovery of highly potent HDAC8 PROTACs with anti-tumor activity[J]. Bioorg Chem, 2023, 136: 106546.
[16]	Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer[J]. Pharmacol Ther, 2021, 221: 107753.
[17]	Pittet MJ, Di Pilato M, Garris C, et al. Dendritic cells as shepherds of T cell immunity in cancer[J]. Immunity, 2023, 56(10): 2218-2230.
[18]	Heras-Murillo I, Adán-Barrientos I, Galán M, et al. Dendritic cells as orchestrators of anticancer immunity and immunotherapy[J]. Nat Rev Clin Oncol, 2024, 21(4): 257-277.

Please choose a citation manager

Content to export